CORE--CHEMOTHERAPY AND TOXICOLOGY

申请人描述：（由申请人提供）该核心组件是

APPLICANT'S DESCRIPTION: (provided by Applicant) This core component is composed of laboratory facilities, equipment, and services that will be shared by the four projects of the proposed program. The core is service-oriented in concept. Its objective will be to provide in a timely, efficient, and cost-effective manner the evaluation of the antitumor activity of candidate drugs that may be at various stages of development in the proposed program. Evaluations may range from initial screening (cytotoxicity compared to relevant standard agents) to detailed evaluations in support of an IND application (e.g., dose and treatment schedule optimization). Evaluations will be conducted in an array of in vitro and in vivo models configured to provided a standardized approach to the development of agents with unknown activity but flexible enough to provide additional guidance in the selection of in vivo models (human tumor xenografts) for detailed evaluation of drug activity. These studies may be complemented by evaluations in conventional murine tumor models. This approach, although not exclusive, emphasizes discovery and development of agents active against solid tumors. Data will be presented in terms of comparative IC50 values from in vitro studies and clinically relevant endpoints (e.g., cures, regressions, or prolonged time to treatment failure) from in vivo studies. Dose-response relationships will be assessed in all studies. Use of these data in drug development decision making will be a cooperative effort among the core component leader, the individual project leaders, and the program PI.